Skip to main content
SpringerLink
Log in

Treatment of Childhood Hypertension

  • Chapter
  • First Online:
Pediatric Kidney Disease

  • 2620 Accesses

Abstract

The treatment of hypertension in children involves lifestyle modifications, drug therapy, and at times surgical intervention. Healthy eating patterns, increased exercise, and when appropriate, weight loss are the tenants of lifestyle modifications. Drug therapy is recommended for children with symptomatic hypertension and those children that do not respond to lifestyle modifications. The most common class of antihypertensive drugs used in children are the angiotensin converting enzyme inhibitors and the angiotensin receptor blockers. Surgical and interventional radiology procedures are most often used in the setting of renal vascular hypertension. Interventional procedures include percutaneous balloon angioplasty and surgical revascularization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.

    Google Scholar 

  2. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007;150(6):640–4, 4 e1.

    Article  PubMed  Google Scholar 

  3. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004;113(3 Pt 1):475–82.

    Article  PubMed  Google Scholar 

  4. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40(4):441–7.

    Article  CAS  PubMed  Google Scholar 

  5. Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension. 2008;52(4):631–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. U.S. Department of Health and Human Services. National Institutes of Health. National Heart L, and Blood Diseases. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Blood Pressure. 2004; 04–5230.

    Google Scholar 

  7. Mironov S, Jalife J, Tolkacheva EG. Role of conduction velocity restitution and short-term memory in the development of action potential duration alternans in isolated rabbit hearts. Circulation. 2008;118(1):17–25.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lande MB, Carson NL, Roy J, Meagher CC. Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. Hypertension. 2006;48(1):40–4.

    Article  CAS  PubMed  Google Scholar 

  9. Lande MB, Kupferman JC, Adams HR. Neurocognitive alterations in hypertensive children and adolescents. J Clin Hypertens. 2012;14(6):353–9.

    Article  Google Scholar 

  10. Cha SD, Patel HP, Hains DS, Mahan JD. The effects of hypertension on cognitive function in children and adolescents. Int J Pediatr. 2012;2012:891094.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Tracy RE, Newman 3rd WP, Wattigney WA, Berenson GS. Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. Am J Med Sci. 1995;310 Suppl 1:S37–41.

    Article  PubMed  Google Scholar 

  12. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension. 2007;50(2):417–23.

    Article  CAS  PubMed  Google Scholar 

  13. Holterman AX, Browne A, Tussing L, Gomez S, Phipps A, Browne N, et al. A prospective trial for laparoscopic adjustable gastric banding in morbidly obese adolescents: an interim report of weight loss, metabolic and quality of life outcomes. J Pediatr Surg. 2010;45(1):74–8; discussion 8-9.

    Article  PubMed  Google Scholar 

  14. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary guidelines for Americans 2010. 7. Available from: www.dietaryguidelines.gov. http://health.gov/dietaryguidelines/dga2010/DietaryGuidelines2010.pdf.

  15. Yang Q, Zhang Z, Kuklina EV, Fang J, Ayala C, Hong Y, et al. Sodium intake and blood pressure among US children and adolescents. Pediatrics. 2012;130(4):611–9.

    Article  PubMed  Google Scholar 

  16. Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med. 2001;134(12):1106–14.

    Article  CAS  PubMed  Google Scholar 

  17. Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr. 2002;76(1):93–9.

    CAS  PubMed  Google Scholar 

  18. National Center for Chronic Disease Prevention and Health Promotion. Divisions of Nutrition, Physical activity, and obesity. State indicator report on fruits and vegetables 2013. Available from: www.cdc.gov.

  19. U.S. Department of Health and Human Services. Physical activity guidelines for Americans 2008. Available from: www.health.gov/paguidelines.

  20. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117–24.

    Article  CAS  PubMed  Google Scholar 

  21. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3–10.

    Article  CAS  PubMed  Google Scholar 

  22. Centers for Disease Control. CDC clinical growth charts 2000. Available from: www.cdc.gov/growthcharts.

  23. Acadamies IoMotN. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academy Press; 2002.

    Google Scholar 

  24. U.S. Department of Health and Human Services. National Institutes of Health. National Heart L, and Blood Institute. DASH eating plan. Lower you blood pressure. 2006; 06–4082.

    Google Scholar 

  25. United States Department of Agriculture. Center for Nutrition Policy and Promotion. USDA Food Patterns. Available from: http://www.cnpp.usda.gov/USDAFoodPatterns.htm.

  26. Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque D, Martin M, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics. 1988;82(1):16–23.

    CAS  PubMed  Google Scholar 

  27. Couch SC, Saelens BE, Levin L, Dart K, Falciglia G, Daniels SR. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. J Pediatr. 2008;152(4):494–501.

    Article  PubMed  Google Scholar 

  28. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580–5.

    Article  CAS  PubMed  Google Scholar 

  29. Chen J, Gu D, Huang J, Rao DC, Jaquish CE, Hixson JE, et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009;373(9666):829–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14(6):383–7.

    Article  CAS  Google Scholar 

  31. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA: J Am Med Assoc. 2001;285(21):2719–28.

    Article  CAS  Google Scholar 

  32. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet. 2000;356(9246):1949–54.

    Article  CAS  PubMed  Google Scholar 

  33. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–62.

    Article  CAS  PubMed  Google Scholar 

  34. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol: JASN. 2007;18(6):1880–8.

    Article  CAS  PubMed  Google Scholar 

  35. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis: Off J Natl Kidney Found. 2000;35(6):1155–65.

    Article  CAS  Google Scholar 

  36. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis: Off J Natl Kidney Found. 1993;22(1):202–6.

    Article  CAS  Google Scholar 

  37. ClinicalTrials.gov. NCT01150357 safety and efficacy of Aliskiren in pediatric hypertensive patients 6–17 years of age 2013. Available from: www.clinicaltrials.gov.

  38. Miller K, Atkin B, Rodel Jr PV, Walker JF. Enalapril: a well-tolerated and efficacious agent for the pediatric hypertensive patient. J Cardiovasc Pharmacol. 1987;10 Suppl 7:S154–6.

    Article  PubMed  Google Scholar 

  39. Morsi MR, Madina EH, Anglo AA, Soliman AT. Evaluation of captopril versus reserpine and frusemide in treating hypertensive children with acute post-streptococcal glomerulonephritis. Acta Paediatr. 1992;81(2):145–9.

    Article  CAS  PubMed  Google Scholar 

  40. Bendig L, Temesvari A. Indications and effects of captopril therapy in childhood. Acta Physiol Hung. 1988;72(Suppl):121–9.

    PubMed  Google Scholar 

  41. Sagat T, Sasinka M, Furkova K, Milovsky V, Riedel R, Tordova E. Treatment of renal hypertension in children by captopril. Clin Exp Hypertens A Theory Pract. 1986;8(4–5):853–7.

    Article  CAS  Google Scholar 

  42. Callis L, Vila A, Castellanos J, Gras X. Long-term treatment with captopril in paediatric patients with severe hypertension and chronic renal failure. Postgrad Med J. 1986;62 Suppl 1:106–7.

    PubMed  Google Scholar 

  43. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870–80.

    Article  CAS  PubMed  Google Scholar 

  44. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.

    Article  CAS  PubMed  Google Scholar 

  45. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112(5):805–10.

    Article  CAS  PubMed  Google Scholar 

  46. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O’Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103(5):799–805.

    Article  CAS  PubMed  Google Scholar 

  47. Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, et al. Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52(2):222–8.

    Article  CAS  PubMed  Google Scholar 

  48. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R, et al. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323–30.

    Article  CAS  PubMed  Google Scholar 

  49. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28(5):1083–90.

    Article  CAS  PubMed  Google Scholar 

  50. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2 Pt 1):183–90.

    Article  CAS  PubMed  Google Scholar 

  51. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens. 2008;10(10):743–50.

    Article  CAS  Google Scholar 

  52. Wells T, Blumer J, Meyers KE, Neto JP, Meneses R, Litwin M, et al. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens. 2011;13(5):357–65.

    Article  CAS  Google Scholar 

  53. Wells TG, Portman R, Norman P, Haertter S, Davidai G, Fei W. Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension. Clin Pediatr. 2010;49(10):938–46.

    Article  Google Scholar 

  54. Bianchetti MG, Caflisch M, Oetliker OH. Cough and converting enzyme inhibitors. Eur J Pediatr. 1992;151(3):225–6.

    Article  CAS  PubMed  Google Scholar 

  55. von Vigier RO, Mozzettini S, Truttmann AC, Meregalli P, Ramelli GP, Bianchetti MG. Cough is common in children prescribed converting enzyme inhibitors. Nephron. 2000;84(1):98.

    Article  Google Scholar 

  56. Blowey DL. Safety of the newer antihypertensive agents in children. Expert Opin Drug Saf. 2002;1(1):39–43.

    Article  CAS  PubMed  Google Scholar 

  57. Li DK, Yang C, Andrade S, Tavares V, Ferber JR. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Sedman AB, Kershaw DB, Bunchman TE. Recognition and management of angiotensin converting enzyme inhibitor fetopathy. Pediatr Nephrol. 1995;9(3):382–5.

    Article  CAS  PubMed  Google Scholar 

  59. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol. 2000;15(3–4):302–16.

    Article  CAS  PubMed  Google Scholar 

  60. Sinaiko AR. Clinical pharmacology of converting enzyme inhibitors, calcium channel blockers and diuretics. J Hum Hypertens. 1994;8(5):389–94.

    CAS  PubMed  Google Scholar 

  61. Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens. 2000;13(10):1061–6.

    Article  CAS  PubMed  Google Scholar 

  62. Silverstein DM, Palmer J, Baluarte HJ, Brass C, Conley SB, Polinsky MS. Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant. 1999;3(4):288–92.

    Article  CAS  PubMed  Google Scholar 

  63. Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol. 1999;13(4):304–10.

    Article  CAS  PubMed  Google Scholar 

  64. Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol. 2002;17(1):35–40.

    Article  PubMed  Google Scholar 

  65. Flynn JT. Nifedipine in the treatment of hypertension in children. J Pediatr. 2002;140(6):787–8.

    Article  PubMed  Google Scholar 

  66. Sinaiko AR, Daniels SR. The use of short-acting nifedipine in children with hypertension: another example of the need for comprehensive drug testing in children. J Pediatr. 2001;139(1):7–9.

    Article  CAS  PubMed  Google Scholar 

  67. Truttmann AC, Zehnder-Schlapbach S, Bianchetti MG. A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises. Pediatr Nephrol. 1998;12(3):259.

    CAS  PubMed  Google Scholar 

  68. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA: J Am Med Assoc. 1995;274(8):620–5.

    Article  CAS  Google Scholar 

  69. Gauthier B, Trachtman H. Short-acting nifedipine. Pediatr Nephrol. 1997;11(6):786–7.

    CAS  PubMed  Google Scholar 

  70. Ellison D. Adaptation to diuretic drugs. In: Seldin D, Giebisch G, editors. Diuretic agents: clinical physiology and pharmacology. San Diego: Academic; 1997. p. 209–32.

    Chapter  Google Scholar 

  71. Bachmann H. Propranolol versus chlorthalidone – a prospective therapeutic trial in children with chronic hypertension. Helv Paediatr Acta. 1984;39(1):55–61.

    CAS  PubMed  Google Scholar 

  72. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17(5):345–50.

    Article  PubMed  Google Scholar 

  73. Griswold WR, McNeal R, Mendoza SA, Sellers BB, Higgins S. Propranolol as an antihypertensive agent in children. Arch Dis Child. 1978;53(7):594–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Potter DE, Schambelan M, Salvatierra Jr O, Orloff S, Holliday MA. Treatment of high-renin hypertension with propranolol in children after renal transplantation. J Pediatr. 1977;90(2):307–11.

    Article  CAS  PubMed  Google Scholar 

  75. Falkner B, Lowenthal DT, Affrime MB. The pharmacodynamic effectiveness of metoprolol in adolescent hypertension. Pediatr Pharmacol. 1982;2(1):49–55.

    CAS  Google Scholar 

  76. Falkner B, Lowenthal DT, Onesti G. Dynamic exercise response in hypertensive adolescent on clonidine therapy: clonidine therapy in adolescent hypertension. Pediatr Pharmacol. 1980;1(2):121–8.

    CAS  Google Scholar 

  77. Falkner B, Onesti G, Lowenthal DT, Affrime MB. Effectiveness of centrally acting drugs and diuretics in adolescent hypertension. Clin Pharmacol Ther. 1982;32(5):577–83.

    Article  CAS  PubMed  Google Scholar 

  78. Walson PD, Rath A, Kilbourne K, Deitch MW. Guanabenz for adolescent hypertension. Pediatr Pharmacol. 1984;4(1):1–6.

    CAS  Google Scholar 

  79. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407–23.

    Article  PubMed  Google Scholar 

  80. Pennisi AJ, Takahashi M, Bernstein BH, Singsen BH, Uittenbogaart C, Ettenger RB, et al. Minoxidil therapy in children with severe hypertension. J Pediatr. 1977;90(5):813–9.

    Article  CAS  PubMed  Google Scholar 

  81. Sinaiko AR, Mirkin BL. Management of severe childhood hypertension with minoxidil: a controlled clinical study. J Pediatr. 1977;91(1):138–42.

    Article  CAS  PubMed  Google Scholar 

  82. Brady TM, Schneider MF, Flynn JT, Cox C, Samuels J, Saland J, et al. Carotid intima-media thickness in children with CKD: results from the CKiD study. Clin J Am Soc Nephrol: CJASN. 2012;7(12):1930–7.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Furth SL, Abraham AG, Jerry-Fluker J, Schwartz GJ, Benfield M, Kaskel F, et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol: CJASN. 2011;6(9):2132–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. ET Group, Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639–50.

    Article  Google Scholar 

  85. Lande MB, Gerson AC, Hooper SR, Cox C, Matheson M, Mendley SR, et al. Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study. Clin J Am Soc Nephrol: CJASN. 2011;6(8):1831–7.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, et al. Masked hypertension associates with left ventricular hypertrophy in children with CKD. J Am Soc Nephrol: JASN. 2010;21(1):137–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Sinha MD, Tibby SM, Rasmussen P, Rawlins D, Turner C, Dalton RN, et al. Blood pressure control and left ventricular mass in children with chronic kidney disease. Clin J Am Soc Nephrol: CJASN. 2011;6(3):543–51.

    Article  PubMed  PubMed Central  Google Scholar 

  88. KDIGO. Clinical practice guideline for the management of blood pressure and chronic kidney disease. Kidney Int Suppl. 2012;2:337.

    Article  Google Scholar 

  89. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24(6):1101–12.

    Article  PubMed  Google Scholar 

  90. Singh D, Akingbola O, Yosypiv I, El-Dahr S. Emergency management of hypertension in children. Int J Nephrol. 2012;2012:420247.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Thomas CA, Moffett BS, Wagner JL, Mott AR, Feig DI. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med: J Soc Crit Care Med World Fed Pediatr Intensiv Crit Care Soc. 2011;12(1):28–32.

    Article  Google Scholar 

  92. Levene MI, Gibson NA, Fenton AC, Papathoma E, Barnett D. The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants. Dev Med Child Neurol. 1990;32(7):567–74.

    Article  CAS  PubMed  Google Scholar 

  93. Marshalleck F. Pediatric arterial interventions. Tech Vasc Interv Radiol. 2010;13(4):238–43.

    Article  PubMed  Google Scholar 

  94. Shroff R, Roebuck DJ, Gordon I, Davies R, Stephens S, Marks S, et al. Angioplasty for renovascular hypertension in children: 20-year experience. Pediatrics. 2006;118(1):268–75.

    Article  PubMed  Google Scholar 

  95. Huang Y, Duncan AA, McKusick MA, Milliner DS, Bower TC, Kalra M, et al. Renal artery intervention in pediatric and adolescent patients: a 20-year experience. Vasc Endovasc Surg. 2007;41(6):490–9.

    Article  Google Scholar 

  96. Srinivasan A, Krishnamurthy G, Fontalvo-Herazo L, Nijs E, Keller MS, Meyers K, et al. Angioplasty for renal artery stenosis in pediatric patients: an 11-year retrospective experience. J Vasc Interv Radiol: JVIR. 2010;21(11):1672–80.

    Article  PubMed  Google Scholar 

  97. Stanley JC, Criado E, Upchurch Jr GR, Brophy PD, Cho KJ, Rectenwald JE, et al. Pediatric renovascular hypertension: 132 primary and 30 secondary operations in 97 children. J Vasc Surg. 2006;44(6):1219–28; discussion 28-9.

    Article  PubMed  Google Scholar 

  98. Baez-Trinidad LG, Lendvay TS, Broecker BH, Smith EA, Warshaw BL, Hymes L, et al. Efficacy of nephrectomy for the treatment of nephrogenic hypertension in a pediatric population. J Urol. 2003;170(4 Pt 2):1655–7; discussion 8.

    Article  PubMed  Google Scholar 

  99. Tash JA, Stock JA, Hanna MK. The role of partial nephrectomy in the treatment of pediatric renal hypertension. J Urol. 2003;169(2):625–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatrics/Pharmacology, Children’s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas, MO, 64108, USA

    Douglas L. Blowey

Authors
  1. Douglas L. Blowey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas L. Blowey .

Editor information

Editors and Affiliations

  1. Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada

    Denis F. Geary

  2. Division of Pediatric Nephrology, University of Heidelberg, Heidelberg, Germany

    Franz Schaefer

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Blowey, D.L. (2016). Treatment of Childhood Hypertension. In: Geary, D., Schaefer, F. (eds) Pediatric Kidney Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-52972-0_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-52972-0_51

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-52970-6

  • Online ISBN: 978-3-662-52972-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation